Kyle C. Molina

913 total citations · 1 hit paper
41 papers, 477 citations indexed

About

Kyle C. Molina is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Kyle C. Molina has authored 41 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 18 papers in Epidemiology and 10 papers in Pharmacology. Recurrent topics in Kyle C. Molina's work include SARS-CoV-2 and COVID-19 Research (9 papers), COVID-19 Clinical Research Studies (9 papers) and Antimicrobial Resistance in Staphylococcus (9 papers). Kyle C. Molina is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (9 papers), COVID-19 Clinical Research Studies (9 papers) and Antimicrobial Resistance in Staphylococcus (9 papers). Kyle C. Molina collaborates with scholars based in United States, Mexico and Canada. Kyle C. Molina's co-authors include Matthew A. Miller, Martin Kršák, Scott W. Mueller, Tyree H. Kiser, Vanthida Huang, Taylor Morrisette, Seth Russell, Nichole E. Carlson, Laurel Beaty and David Mayer and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Kyle C. Molina

38 papers receiving 471 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study

2023 75 citations Neil Krishan Aggarwal, Kyle C. Molina et al. The Lancet Infectious Diseases profile →

Peers

Kyle C. Molina

EPIDE

PHARM

Noah Wald‐Dickler United States

Odaliz Abreu-Lanfranco United States

Bhagyashri Navalkele United States

Abi Jenkins United Kingdom

Rujipas Sirijatuphat Thailand

Juan Frasquet Spain

Akari Shigemi Japan

Sean Nguyen United States

Linda Bussini Italy

Anupop Jitmuang Thailand

Noah Wald‐Dickler United States

Kyle C. Molina

237 ×0.7

174 ×1.1

EPIDE

34 ×0.3

PHARM

62 ×0.8

36 ×0.6

Citations per year, relative to Kyle C. Molina Kyle C. Molina (= 1×) peers Noah Wald‐Dickler

Countries citing papers authored by Kyle C. Molina

Since Specialization

Citations

This map shows the geographic impact of Kyle C. Molina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle C. Molina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle C. Molina more than expected).

Fields of papers citing papers by Kyle C. Molina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle C. Molina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle C. Molina. The network helps show where Kyle C. Molina may publish in the future.

Co-authorship network of co-authors of Kyle C. Molina

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle C. Molina. A scholar is included among the top collaborators of Kyle C. Molina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle C. Molina. Kyle C. Molina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kršák, Martin, et al.. (2025). Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium?. Clinical Orthopaedics and Related Research. 483(7). 1225–1233. 3 indexed citations

Jeffres, Meghan N., et al.. (2024). Evaluation of Oral Amoxicillin/Clavulanate for Urinary Tract Infections Caused by Ceftriaxone Non-Susceptible Enterobacterales. SHILAP Revista de lepidopterología. 12(2). 60–60. 1 indexed citations

Mueller, Scott W., et al.. (2024). Bone and Skin/Subcutaneous Tissue Concentrations of Cefiderocol During Treatment of Extensively Drug-Resistant Pseudomonas aeruginosa. Journal of Burn Care & Research. 45(3). 808–810. 2 indexed citations

Scherger, Sias, Kyle C. Molina, Alan G. Palestine, Paula E. Pecen, & Valida Bajrovic. (2024). Cytomegalovirus Retinitis in the Modern Era of Solid Organ Transplantation. Transplantation Proceedings. 56(7). 1696–1701. 1 indexed citations

Aggarwal, Neil R., Laurel Beaty, Tellen D. Bennett, et al.. (2024). Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study. The Lancet Regional Health - Americas. 31. 100693–100693. 3 indexed citations

Wendel, Sarah K., Adane F. Wogu, Nichole E. Carlson, et al.. (2024). Effectiveness of subcutaneous monoclonal antibody treatment in emergency department outpatients with COVID‐19. SHILAP Revista de lepidopterología. 5(1). e13116–e13116. 1 indexed citations

Molina, Kyle C., Brandon Webb, Laurel Beaty, et al.. (2024). Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5. BMC Infectious Diseases. 24(1). 802–802. 2 indexed citations

Miller, Matthew A., et al.. (2024). Prospective evaluation of single‐dose aminoglycosides for treatment of complicated cystitis in the emergency department. Academic Emergency Medicine. 31(7). 649–655.

Abidi, Maheen Z., et al.. (2023). Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis. Transplant Infectious Disease. 25(5). e14104–e14104. 1 indexed citations

10.

Molina, Kyle C., Laurel Beaty, Tellen D. Bennett, et al.. (2023). Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5. International Journal of Infectious Diseases. 132. 34–39. 7 indexed citations

11.

Molina, Kyle C., Stefan Sillau, Sias Scherger, et al.. (2023). Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: a global research network with a follow-up multicenter case-control study. Therapeutic Advances in Infectious Disease. 10. 2018394297–2018394297. 9 indexed citations

12.

Aggarwal, Neil Krishan, Kyle C. Molina, Laurel Beaty, et al.. (2023). Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. The Lancet Infectious Diseases. 23(6). 696–705. 75 indexed citations breakdown →

13.

Molina, Kyle C.. (2023). Best Practices in the Management of Infectious Complications for Patients With Cancer: Management of Febrile Neutropenia. Journal of the Advanced Practitioner in Oncology. 14(3). 201–206. 3 indexed citations

14.

Morrisette, Taylor, Kyle C. Molina, Scott W. Mueller, et al.. (2022). Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success. Open Forum Infectious Diseases. 9(6). ofac028–ofac028. 12 indexed citations

15.

Aggarwal, Neil R., Laurel Beaty, Tellen D. Bennett, et al.. (2022). Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase. International Journal of Infectious Diseases. 128. 310–317. 17 indexed citations

16.

Douin, David J., Adane F. Wogu, Laurel Beaty, et al.. (2022). Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients. BMC Infectious Diseases. 22(1). 818–818. 2 indexed citations

17.

Molina, Kyle C., Taylor Morrisette, Matthew A. Miller, Vanthida Huang, & Douglas N. Fish. (2020). The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrobial Agents and Chemotherapy. 64(7). 23 indexed citations

18.

Molina, Kyle C., et al.. (2019). Utilization of Augmented Renal Clearance in Trauma Intensive Care Scoring System to Improve Vancomycin Dosing in Trauma Patients at Risk for Augmented Renal Clearance. Surgical Infections. 21(1). 43–47. 8 indexed citations

19.

Molina, Kyle C., Kathleen A. Fairman, & David A. Sclar. (2018). Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits. Drug Healthcare and Patient Safety. Volume 10. 37–43. 14 indexed citations

20.

Molina, Kyle C. & Vanthida Huang. (2016). Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections. Current Infectious Disease Reports. 18(12). 47–47. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact